These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1940615)

  • 21. Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals.
    Weinhold KJ; Lyerly HK; Matthews TJ; Tyler DS; Ahearne PM; Stine KC; Langlois AJ; Durack DT; Bolognesi DP
    Lancet; 1988 Apr; 1(8591):902-5. PubMed ID: 2895830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection.
    Ljunggren K; Karlson A; Fenyö EM; Jondal M
    Clin Exp Immunol; 1989 Feb; 75(2):184-9. PubMed ID: 2649286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-dependent cellular cytotoxicity in HIV infections.
    Ahmad A; Menezes J
    FASEB J; 1996 Feb; 10(2):258-66. PubMed ID: 8641559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Up-regulation of natural killer activity of human immunodeficiency virus-infected patients by in vitro-differentiated macrophages.
    Chang ZL; Huang XL; Rinaldo C; Herberman RB; Whiteside TL
    Clin Immunol Immunopathol; 1989 Apr; 51(1):133-9. PubMed ID: 2924437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC.
    Lyerly HK; Reed DL; Matthews TJ; Langlois AJ; Ahearne PA; Petteway SR; Weinhold KJ
    AIDS Res Hum Retroviruses; 1987; 3(4):409-22. PubMed ID: 2833917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-HIV-1 ADCC: clinical and therapeutic implications.
    Weinhold KJ
    Biotechnol Ther; 1991; 2(1-2):147-57. PubMed ID: 1845118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity.
    Hu PF; Hultin LE; Hultin P; Hausner MA; Hirji K; Jewett A; Bonavida B; Detels R; Giorgi JV
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):331-40. PubMed ID: 7552495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of lymphokine-activated killer activity during HIV infection: role of HIV-1 gp41 synthetic peptides.
    Cauda R; Tumbarello M; Ortona L; Kennedy RC; Shuler KR; Chanh TC; Kanda P
    Nat Immun Cell Growth Regul; 1990; 9(6):366-75. PubMed ID: 2087245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.
    Johansson SE; Rollman E; Chung AW; Center RJ; Hejdeman B; Stratov I; Hinkula J; Wahren B; Kärre K; Kent SJ; Berg L
    Viral Immunol; 2011 Oct; 24(5):359-68. PubMed ID: 21958370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type I.
    Böttiger B; Ljunggren K; Karlsson A; Krohn K; Fenyö EM; Jondal M; Biberfeld G
    Clin Exp Immunol; 1988 Sep; 73(3):339-42. PubMed ID: 3208445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NKG2D Acts as a Co-Receptor for Natural Killer Cell-Mediated Anti-HIV-1 Antibody-Dependent Cellular Cytotoxicity.
    Parsons MS; Richard J; Lee WS; Vanderven H; Grant MD; Finzi A; Kent SJ
    AIDS Res Hum Retroviruses; 2016; 32(10-11):1089-1096. PubMed ID: 27487965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of acute exercise on lymphocyte subsets, natural killer cells, proliferative responses, and cytokines in HIV-seropositive persons.
    Ullum H; Palmø J; Halkjaer-Kristensen J; Diamant M; Klokker M; Kruuse A; LaPerriere A; Pedersen BK
    J Acquir Immune Defic Syndr (1988); 1994 Nov; 7(11):1122-33. PubMed ID: 7932079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation.
    Gooneratne SL; Center RJ; Kent SJ; Parsons MS
    Clin Exp Immunol; 2016 Apr; 184(1):101-9. PubMed ID: 26647083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical progression of HIV infection: role of NK cells.
    Bruunsgaard H; Pedersen C; Skinhøj P; Pedersen BK
    Scand J Immunol; 1997 Jul; 46(1):91-5. PubMed ID: 9246213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural immunity and HIV disease progression.
    Ullum H; Cozzi Lepri A; Aladdin H; Katzenstein T; Victor J; Phillips AN; Gerstoft J; Skinhøj P; Klarlund Pedersen B
    AIDS; 1999 Apr; 13(5):557-63. PubMed ID: 10203380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.